BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System
January 14 2020 - 7:52AM
- Company allowed a fifth utility patent
- Claims address methods for removing voltage offset from
biomedical signals
- Eleven additional patent applications covering PURE
EPTM System are currently pending
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the US Patent Office allowed a fifth
utility patent covering its PURE EPTM System. The recently allowed
patent application number 16/195,562 entitled "APPARATUS AND
METHODS FOR REMOVING A LARGE-SIGNAL VOLTAGE OFFSET FROM A
BIOMEDICAL SIGNAL" was filed on November 19, 2018. The claims
address methods for removing a voltage offset from a biomedical
signal, such as low amplitude cardiac signals during an ablation
procedure in the presence of noise.
The allowed patent application complements BioSig’s expanding
patent portfolio, which now includes five allowed/issued
patents. Eleven additional worldwide utility patent applications
are pending covering various aspects of its PURE EPTM System for
recording, measuring, calculating and displaying of
electrocardiograms during cardiac ablation procedures. BioSig also
has 21 allowed/issued worldwide design patents, which cover various
features of its display screens and graphical user interface for
enhanced visualization of biomedical signals.
"We are pleased to announce this newest patent allowance, which
further acknowledges the novelty of our advanced biomedical signal
processing technology,” commented Kenneth L. Londoner, Chairman and
CEO of BioSig Technologies, Inc.
The PURE EPTM System is indicated as a computerized system
intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory
under the supervision of licensed healthcare practitioners who are
responsible for interpreting the data. About BioSig
Technologies BioSig Technologies is a medical technology
company developing a proprietary biomedical signal processing
platform designed to improve the electrophysiology (EP) marketplace
(www.biosig.com). Led by a proven management team and a veteran
Board of Directors, BioSig Technologies is preparing to
commercialize its PURE EPTM System. The technology has been
developed to address an unmet need in a large and growing
market.
The Company’s first product, PURE EPTM System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The system is indicated for use under the supervision of licensed
healthcare practitioners who are responsible for interpreting the
data. This novel cardiac signal acquisition and display system is
engineered to assist electrophysiologists in clinical
decision-making during electrophysiology procedures in patients
with abnormal heart rates and rhythms. BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for
the prevalent and potentially deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and received FDA 510(k)
clearance for the PURE EPTM System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024